Dear Nitrosamines expert,
I have two points making me slight confused regarding setting limits of nitrosamines.
- If there are theoretically Potential nitrosamines for example; NDMA and N-nitroso compound for example; N-nitroso Sitagliptin.
My question is; there will be two limits for NDMA and N-nitroso Sitagliptin based on MDD of the API or there will be a Single limit for both nitrosamines where Acceptance daily intake of the most potent nitrosamine will be taken into consideration for calculation of both nitrosamines as Sum limit.
- If the drug product has potential risk for nitrosamines formation; an accelerated stability study will be carried where the high temperature can trigger nitrosamines formation which can be risky especially for 6M interval while in long term ; there will be no longer that risk; my Question is; Can Accelerated stability study’s elevated temperature induce nitrosamines formation?.
My regards,